Maneesh Jain is the Co-Founder and CEO of Mirvie, a company pioneering a new frontier in prenatal care. Its goal is to predict pregnancy complications before they happen using RNA and machine learning. For Jain, building breakthrough healthcare technology is part of a much longer story. His path has always been driven by curiosity, precision, and a desire to create real-world impact.
“I was just fundamentally curious,” he shared in a 2023 interview. “From my youngest days… curious about how things worked the way they did.” That curiosity led him to study physics at Caltech and later earn a master’s degree in applied physics from Stanford. But midway through graduate school, he made a bold shift.
After realizing that most breakthroughs in laser physics had happened decades earlier, Jain turned his attention to the life sciences, specifically the emerging Human Genome Project. Despite not having studied biology since high school, he jumped into the field, drawn by its potential to shape a fast-moving area of discovery.
That instinct to move toward the edge of innovation has defined his career. Over the last two decades, he has focused on turning scientific breakthroughs into technologies that expand what medicine can detect and treat. From decoding DNA at scale to identifying cancer through blood samples, his ventures have made the human body more measurable and science more actionable.
With Mirvie, Jain is applying that same vision to maternal health. Despite how high the stakes are, pregnancy care still lacks personalized and predictive tools.
“It’s kind of a black box,” he says. “We know so little about something that matters so much.” One in five pregnancies involves complications, yet the current model of care is largely reactive. Providers often have to wait until symptoms emerge, when it may already be too late for meaningful intervention.
Mirvie’s RNA platform analyzes a simple blood sample to uncover the unique biological signals of each pregnancy. Built over seven years and supported by clinical studies involving over 15,000 pregnancies, the platform has been shown to predict 90% of preterm preeclampsia cases and 60% of severe fetal growth restriction cases months in advance. This opens the door to earlier, more personalized care and better outcomes for both parent and baby.
The company’s vision has drawn strong support from investors, including General Catalyst. As partner Holly Maloney noted, “Pregnancy health is one of the most overlooked areas of medicine.” And it is this very problem that Jain and Mirvie aim to solve.
